A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

To better understand the safety and tolerability of ALKS 4230 in humans

Key facts

Study ID: NCT02799095
Run by: Mural Oncology, Inc
People needed: 243
Starts: 2016-09-14
Expected to finish: 2023-08-02
Last updated by the study team: 2025-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

For Part A, the subject has histological or cytological evidence of a solid tumor; for Part B, the subject has a diagnosis of melanoma or renal cell carcinoma
All subjects must have advanced solid tumors that have returned after treatment with established approved therapies or be intolerant of established therapies
Subjects enrolled in Part B or Part C must have at least 1 lesion that may qualify as a target lesion
Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and has an estimated life expectancy of at least 3 months
Subject must have adequate hematologic reserve
Subjects must have adequate liver function
Subjects must have adequate kidney function
Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery
Subjects who have received investigational agents must wait at least 4 weeks
Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered. A female not of childbearing potential is one who has undergone bilateral oophorectomies or who is postmenopausal, defined as >45 years of age and without a menstrual period for 12 consecutive months
Meets contraceptive requirements defined in the protocol
Additional criteria may apply

You may not qualify if…

Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study
Subjects with an active infection or with a fever >/= 38.5 degrees C within 3 days of the first scheduled day of dosing for Cycle 1
Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable
Subjects have a mean QT interval corrected by the Fridericia Correction formula value of >470 msec (in females) or >450 msec (in males)
Subjects with known hypersensitivity to any components of ALKS 4230
Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
Subjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
Subjects who developed autoimmune disorders while on prior immunotherapy, including pneumonitis, nephritis, and neuropathy
Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study
The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or C, or active tuberculosis, or has a known history of tuberculosis
Subjects with dyspnea at rest of requiring oxygen therapy
Subjects active autoimmune disease requiring systemic treatment within the past 30 days
Subjects who received radiotherapy within the last 4 weeks before start of study treatment administration with the exception of limited field palliative radiotherapy
Subjects who have received systemic immunomodulatory agents within 28 days prior to C1D1.
Subjects who have received administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day1.
Prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant recipients
Subjects who have received prior IL-2 based or IL-15 based cytokine therapy
Additional criteria may apply

Where it is running

Mural Oncology Investigational Site — Denver, Colorado, United States
Mural Oncology Investigational Site — Port Saint Lucie, Florida, United States
Mural Oncology Investigational Site — Tampa, Florida, United States
Mural Oncology Investigational Site — Lexington, Kentucky, United States
Mural Oncology Investigational Site — Boston, Massachusetts, United States
Mural Oncology Investigational Site — Detroit, Michigan, United States
Mural Oncology Investigational Site — Buffalo, New York, United States
Mural Oncology Investigational Site — New York, New York, United States
Mural Oncology Investigational Site — Cleveland, Ohio, United States
Mural Oncology Investigational Site — Dallas, Texas, United States
Mural Oncology Investigational Site — Fairfax, Virginia, United States
Mural Oncology Investigational Site — Spokane, Washington, United States
Mural Oncology Investgational Site — Albury, New South Wales, Australia
Mural Oncology Investigational Site — Waratah, New South Wales, Australia
Mural Oncology Investigational Site — Brussels, MO, Belgium
Mural Oncology Investigational Site — Kortrijk, West-Vlaanderen, Belgium
Mural Oncology Investigational Site — Edmonton, Alberta, Canada
Mural Oncology Investigational Site — Hamilton, Ontario, Canada
Alkermes Investigational Site — Toronto, Ontario, Canada
Mural Oncology Investigational Site — Montreal, Quebec, Canada
Mural Oncology Investigational Site — Québec, Quebec, Canada
Mural Oncology Investigational Site — Skorzewo, Poznan, Poland
Mural Oncology Investigational Site — Daejeon, South Korea
Mural Oncology Investigational Site — Seoul, South Korea
Mural Oncology Investigational Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.